Comparing the cost-effectiveness of two screening strategies for latent tuberculosis infection in Portugal (original) (raw)
Cost-Effectiveness of Quantiferon®-TB Gold-In-Tube Versus Tuberculin Skin Testing for Contact Screening and Treatment of Latent Tuberculosis Infection in Brazil
Rosangela Caetano
PLoS ONE, 2013
View PDFchevron_right
Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis
Jim Huggett
BMC Pulmonary Medicine, 2010
View PDFchevron_right
Cost-Effectiveness of QuantiFERON®-TB Gold In-Tube versus Tuberculin Skin Testing for Contact Screening for Latent Tuberculosis Infection in Brazil
Rosangela Caetano
PlosOne, 2013
View PDFchevron_right
Systematic review of cost and cost-effectiveness of different TB-screening strategies
Roland Diel
BMC Health Services Research, 2011
View PDFchevron_right
Direct costs of three models for the screening of latent tuberculosis infection
Jean-pierre Zellweger
European Respiratory Journal, 2006
View PDFchevron_right
Cost-effectiveness of Tuberculosis Screening in Health Care Workers Is Not Robust
David Perlman
Archives of Internal Medicine, 2009
View PDFchevron_right
Cost-effectiveness of interferon- release assay testing for the treatment of latent tuberculosis
Jean-pierre Zellweger
European Respiratory Journal, 2007
View PDFchevron_right
Lessons learned from implementation of interferon-gamma release assay to screen for latent tuberculosis infection in a large multicenter observational cohort study in Brazil
Elisangela C Silva
2021
View PDFchevron_right
Screening and Treatment of Latent Tuberculosis Among Healthcare Workers at Low, Moderate, and High Risk for Tuberculosis Exposure: A Cost‐Effectiveness Analysis •
Shelley Salpeter
Infection Control and Hospital Epidemiology, 2004
View PDFchevron_right
Tuberculosis screening in Portuguese healthcare workers using the tuberculin skin test and the interferon- release assay
Marcelo Miranda
European Respiratory Journal, 2009
View PDFchevron_right
Screening of healthcare workers for tuberculosis: development and validation of a new health economic model to inform practice
Nazli Eralp
Bmj Open, 2012
View PDFchevron_right
Cost-effectiveness of screening for active cases of tuberculosis in Flanders, Belgium
Jean Macq
Bulletin of the World Health Organization, 2017
View PDFchevron_right
Tuberculin Skin Testing versus Interferon-Gamma Release Assay among Users of a Public Health Unit in Northeast Portugal
Cristina Teixeira
Portuguese Journal of Public Health, 2021
View PDFchevron_right
Estimates of Testing for Latent Tuberculosis Infection and Cost, United States, 2013
Suzanne Marks
Public Health Reports, 2019
View PDFchevron_right
The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review
Robin Christensen
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2018
View PDFchevron_right
Cost-Effectiveness of Annual Screening for Tuberculosis among Italian Healthcare Workers: A Retrospective Study
Andrea Torrente
International Journal of Environmental Research and Public Health, 2020
View PDFchevron_right
Interferon-Gamma Release Assays (IGRAs) for Screening of Latent Tuberculosis Infection (LTBI) in Healthcare Workers
Krit Pongpirul
View PDFchevron_right
Targeted screening and treatment for latent tuberculosis infection using QuantiFERON®-TB Gold is cost-effective in Mexico
Luis Burgos, Sergio Bautista-Arredondo
INT J TUBERC LUNG D, 2009
View PDFchevron_right
Private sector tuberculosis prevention in the US: Characteristics associated with interferon-gamma release assay or tuberculin skin testing
Erin Carlson
PloS one, 2018
View PDFchevron_right
Tuberculosis screening in outpatient healthcare workers: lessons from a high-income, low TB burden country
Roberto Luzzati
The International Journal of Tuberculosis and Lung Disease, 2019
View PDFchevron_right
Scaling up investigation and treatment of household contacts of tuberculosis patients in Brazil: a costeffectiveness and budget impact analysis
Eduardo Faerstein
The Lancet Regional Health - Americas, 2022
View PDFchevron_right
Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil
Elisangela C Silva
Microbiology Spectrum, 2021
View PDFchevron_right
Impact of interferon-γ release assay on the latent tuberculosis cascade of care: a population-based study
Muhammad Morshed
The European respiratory journal, 2017
View PDFchevron_right
A cost-effectiveness evaluation of latent tuberculosis infection screening of a migrant population in Malaysia
Catherine Bowe
Scientific Reports, 2023
View PDFchevron_right
Interferon-γ releasing assay versus tuberculin skin testing for latent tuberculosis infection in targeted screening programs for high risk immigrants
Laura Cordier, Maurizio Ferrarese
Infection, 2010
View PDFchevron_right
TB diagnostic tests: how do we figure out their costs?
Keertan Dheda
Expert Review of Anti-infective Therapy, 2009
View PDFchevron_right
Cost-effectiveness in the diagnosis of tuberculosis: choices in developing countries
Paola Molicotti
The Journal of Infection in Developing Countries, 2014
View PDFchevron_right